v3.26.1
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 16, 2023
Jan. 20, 2017
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 15, 2025
Dec. 14, 2025
Jul. 02, 2024
Jun. 16, 2022
Options                  
Outstanding balance at the beginning of the period (in shares)     6,416,744 3,384,366          
Granted (in shares)     1,000,000 3,460,000          
Exercised (in shares)     (6,667) (34,698)          
Forfeited (in shares)     (3,652,839) (392,924)          
Outstanding balance at the end of the period (in shares)     3,757,238 6,416,744 3,384,366        
Options exercisable at the end of the period (in shares)     2,417,888            
Options vested and expected to vest at end of period (in shares)     3,757,238            
Weighted Average Exercise Price Per Share                  
Outstanding balance at the beginning of the period (in dollars per share)     $ 8.43 $ 13.97          
Granted (in dollars per share)     1.18 2.57          
Exercised (in dollars per share)     2.4 2.68          
Forfeited (in dollars per share)     7.45 4.98          
Outstanding balance at the end of the period (in dollars per share)     7.46 $ 8.43 $ 13.97        
Options exercisable at the end of the period (in dollars per share)     10.76            
Options vested and expected to vest at end of the period (in dollars per share)     $ 7.46            
Weighted Average Remaining Life in Years                  
Outstanding balance     7 years 3 months 10 days 8 years 5 months 4 days 8 years 4 months 24 days        
Options exercisable at end of period     6 years 3 days            
Options vested and expected to vest at end of the period     7 years 3 months 10 days            
Assumptions used to determine grant-date fair value                  
Expected volatility     103.46% 93.92%          
Weighted average risk-free interest rate     3.90% 3.82%          
Expected dividend yield     0.00% 0.00%          
Expected term (in years)     7 years 6 years 5 months 15 days          
Expiration period     10 years            
Unrecognized compensation cost related to non-vested stock options     $ 1,650            
Company's common stock, par value (in dollars per share)     $ 0.001 $ 0.001          
Common stock                  
Options                  
Exercised (in shares)     (6,667) (34,698)          
Stock Option                  
Weighted Average Exercise Price Per Share                  
Granted (in dollars per share)     $ 1 $ 2.04          
Minimum                  
Assumptions used to determine grant-date fair value                  
Vesting period     3 years            
Maximum                  
Assumptions used to determine grant-date fair value                  
Vesting period     4 years            
Weighted Average                  
Assumptions used to determine grant-date fair value                  
Weighted average period for recognition of compensation cost     1 year 8 months 1 day            
Options to purchase common stock                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense     $ 4,899 $ 5,504          
Options to purchase common stock | Research and development                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense     1,031 2,855          
Options to purchase common stock | General and administrative                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Stock Based Compensation Expense     3,868 $ 2,649          
Restricted stock units to purchase common stock                  
Assumptions used to determine grant-date fair value                  
Vested     19,220            
Unrecognized compensation costs related to RSUs granted to employees     $ 17,610            
Unrecognized costs weighted-average period     2 years 9 months 7 days            
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]                  
Outstanding at the beginning     220,000 262,500          
Vested (in shares)     (303,000) (27,500)          
Granted (in shares)     20,799,921            
Cancelled (in shares)     (2,411,700) (15,000)          
Outstanding at the end     18,305,221 220,000 262,500        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value                  
Outstanding at beginning( in dollars per share)     $ 19.4 $ 19.97          
Vested(in dollars per share)     14.21 25.7          
Granted(in dollars per share)     0.98            
Cancelled(in dollars per share)     0.44 17.8          
Outstanding at end(in dollars per share)     $ 1.05 $ 19.4 $ 19.97        
2016 Plan                  
Assumptions used to determine grant-date fair value                  
Annual increase in authorized shares (as a percent)   4.00%              
2016 and 2022 Plan                  
Assumptions used to determine grant-date fair value                  
Number of options or stock awards available for grant under the Plan     9,344,326            
2022 Plan                  
Assumptions used to determine grant-date fair value                  
Number of options or stock awards available for grant under the Plan                 750,000
Shares reserved for issuance               2,000,000  
Additional shares issuable 2,250,000                
2025 Plan                  
Assumptions used to determine grant-date fair value                  
Number of options or stock awards available for grant under the Plan           31,454,785      
Company's common stock, par value (in dollars per share)           $ 0.001      
Company increased authorized shares           500,000,000 250,000,000    
2025 Plan | Common stock                  
Assumptions used to determine grant-date fair value                  
Company increased authorized shares           490,000,000